energast pylostat

---

The gastric environment presents a distinct physiological and microbiological landscape characterised by high acidity, rapid epithelial turnover, and close interaction between mucosal surfaces and microbial factors. Functional disturbances at the gastric level may manifest as dyspeptic symptoms, mucosal sensitivity, or reduced tolerance to environmental and dietary stressors. In some individuals, these disturbances coexist with colonisation by Helicobacter pylori, a bacterium capable of interacting closely with the gastric mucosa.

While eradication of H. pylori infection remains the domain of antibiotic-based medical therapy, nutritional and microbiome-aligned strategies have been explored to support gastric comfort and microbial balance alongside or following standard care. These strategies focus on functional support, not antimicrobial treatment.

Energast Pylostat™ was developed within this framework as a supportive gastric formulation combining Microencapsulated Sodium Butyrate (MSB®) with Saccharomyces boulardii CNCM I-3799 and inactivated Lactobacillus reuteri DSM 17648. The product is explicitly positioned to support gastric comfort and mucosal balance and is not intended to eradicate or treat H. pylori infection.

Gastric mucosal integrity depends on coordinated epithelial renewal, mucus secretion, immune surveillance, and microbial interaction. Disruption of this balance may increase mucosal sensitivity and contribute to functional discomfort. Although butyrate is classically associated with colonic physiology, short-chain fatty acids also exert immunomodulatory and epithelial-supportive effects across the gastrointestinal tract.

MSB® technology enables controlled delivery of sodium butyrate beyond the upper gastrointestinal tract, supporting mucosal environments indirectly through immune and epithelial signalling pathways. This provides a rationale for its inclusion as a foundational support component in gastrointestinal formulations extending beyond the colon.

Saccharomyces boulardii CNCM I-3799 is a probiotic yeast widely studied for its supportive role in gastrointestinal tolerance, particularly during periods of microbial perturbation. Its mechanisms include interaction with luminal factors and modulation of host responses without permanent colonisation.

Inactivated Lactobacillus reuteri DSM 17648 represents a strain-specific, non-viable preparation investigated for its capacity to bind H. pylori cells physically, promoting aggregation and facilitating their removal from the gastric environment. Importantly, this mechanism does not rely on antimicrobial activity, distinguishing it from antibiotic approaches and aligning it with a supportive, non-pharmacological strategy.

The formulation rationale of Energast Pylostat lies in combining mucosal support (MSB®) with strain-specific microbial interaction (DSM 17648) and functional tolerance support (S. boulardii).

Clinical research into gastric microbiome support has focused on functional outcomes such as symptom relief, microbial load modulation, and tolerance during or after medical intervention. Studies evaluating S. boulardii have demonstrated benefits in gastrointestinal tolerance, while investigations of inactivated L. reuteri DSM 17648 have examined its interaction with H. pylori in human subjects.

Parallel research into microencapsulated butyrate has highlighted its role in epithelial and immune modulation, providing a mechanistic foundation for its inclusion in upper gastrointestinal support strategies.

Energast Pylostat is positioned within this functional evidence landscape, clearly distinct from therapeutic or eradication-focused interventions.

In the randomized, placebo-controlled study by Holz et al., supplementation with inactivated Lactobacillus reuteri DSM 17648 was associated with a reduction in H. pylori load as measured by urea breath testing, compared with placebo. Secondary outcomes included improvements in gastric comfort parameters. These findings demonstrate a strain-specific, non-antibiotic mechanism relevant to functional gastric support.

Clinical studies evaluating Saccharomyces boulardii CNCM I-3799 have reported improvements in gastrointestinal tolerance and symptom modulation in various contexts of gut perturbation. While not gastric-specific, these outcomes support its inclusion as a functional stabiliser within gastrointestinal formulations.

In studies assessing microencapsulated sodium butyrate, outcomes related to mucosal integrity and inflammatory modulation have been reported compared with control conditions. Although primarily focused on lower gastrointestinal contexts, these findings support butyrate’s broader role in mucosal support.

Collectively, the evidence supports a coherent rationale for Energast Pylostat as a supportive gastric formulation integrating complementary mechanisms. DSM 17648 provides strain-specific interaction with H. pylori, S. boulardii supports functional tolerance, and MSB® contributes to mucosal and immune balance.

The observed effects are functional and adjunctive, not therapeutic. This distinction is essential for appropriate scientific interpretation and ethical positioning. Energast Pylostat’s value lies in supporting gastric comfort and balance rather than altering disease course.

Energast Pylostat™ represents a scientifically coherent, microbiome-aligned approach to supporting gastric comfort and mucosal balance. By combining MSB® technology, Saccharomyces boulardii CNCM I-3799, and inactivated Lactobacillus reuteri DSM 17648, the formulation integrates epithelial support with strain-specific microbial interaction in a non-pharmacological framework.

Interpreted with appropriate scientific restraint, Energast Pylostat exemplifies a systems-based strategy consistent with modern understanding of gastric microbiology and functional gastrointestinal health.